Furthermore, both upregulated miR-6734-3p and silencing of ZEB2 increased cisplatin-sensitivity in cisplatin-resistant NSCLC (CR-NSCLC) cells. This evidence concerns the gene ZEB2 and non-small cell lung carcinoma.